TargImmune Therapeutics Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
21
- Latest Deal Type
-
M&A
TargImmune Therapeutics General Information
Description
Developer of molecule-based modality intended to assist in drug development to cure novel targeted cancer treatment. The company focuses on research, development, manufacture, exploitation, purchase, and sale of pharmaceutical and diagnostic products and technologies as well as focuses on the development of novel cancer-targeted technology that utilizes a non-viral vector to target and destroy cancer cells, enabling the healthcare sector to avail distinct drugs and treatments in the field of immuno-oncology and personalized therapy.
Contact Information
Website
www.targimmune.com(Operating Subsidiary)
Corporate Office
- Hochbergerstrasse 60C
- 4057 Basel
- Switzerland
Corporate Office
- Hochbergerstrasse 60C
- 4057 Basel
- Switzerland
TargImmune Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 14-Mar-2025 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC | 16-Jul-2021 | Completed | Pre-Clinical Trials | |||
| 5. Early Stage VC | 14-Jul-2020 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 31-Oct-2019 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC | 19-Jul-2019 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 18-Jul-2017 | $15.5M | $17.6M | Completed | Startup | |
| 1. Early Stage VC | 12-Sep-2016 | $2.06M | $2.06M | Completed | Startup |
TargImmune Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 2,000,000 | $0.108840 | $8.16 | $8.16 | 1x | $8.16 | 27.53% | |
| Ordinary | 400,000 | $0.108840 | $5.44 | $5.44 | 1x | $5.44 | 5.51% |
TargImmune Therapeutics Comparisons
Industry
Financing
Details
TargImmune Therapeutics Competitors (15)
One of TargImmune Therapeutics’s 15 competitors is Anaveon, a Venture Capital-Backed company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Anaveon | Venture Capital-Backed | Basel, Switzerland | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Alaunos Therapeutics | Formerly VC-backed | Fort Lauderdale, FL | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Virometix | Venture Capital-Backed | Schlieren, Switzerland |
TargImmune Therapeutics Patents
TargImmune Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026229366-A1 | Egfr-targeting vectors and therapeutics | Pending | 29-Apr-2025 | ||
| WO-2026229365-A1 | Low molecular weight polynucleotides and polyplexes comprising the same | Pending | 29-Apr-2025 | ||
| WO-2025238236-A1 | Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol | Pending | 16-May-2024 | ||
| AU-2023376544-A1 | Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol | Pending | 07-Nov-2022 | ||
| EP-4615510-A1 | Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol | Pending | 07-Nov-2022 | A61K47/60 |
TargImmune Therapeutics Signals
TargImmune Therapeutics Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ENKORE International Enterprises | Venture Capital | Minority | ||
| European Commission | Government | |||
| Genextra | Venture Capital | Minority | ||
| Pagani Ventures | Venture Capital | Minority |
TargImmune Therapeutics Investments (1)
TargImmune Therapeutics’s most recent deal was a Joint Venture with Race Immunotherapeutics. The deal was made on 10-Jul-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Race Immunotherapeutics | 10-Jul-2017 | Joint Venture | Drug Discovery |
TargImmune Therapeutics FAQs
-
When was TargImmune Therapeutics founded?
TargImmune Therapeutics was founded in 2016.
-
Where is TargImmune Therapeutics headquartered?
TargImmune Therapeutics is headquartered in Basel, Switzerland.
-
What is the size of TargImmune Therapeutics?
TargImmune Therapeutics has 21 total employees.
-
What industry is TargImmune Therapeutics in?
TargImmune Therapeutics’s primary industry is Drug Discovery.
-
Is TargImmune Therapeutics a private or public company?
TargImmune Therapeutics is a Private company.
-
What is TargImmune Therapeutics’s current revenue?
The current revenue for TargImmune Therapeutics is .
-
How much funding has TargImmune Therapeutics raised over time?
TargImmune Therapeutics has raised $49.2M.
-
Who are TargImmune Therapeutics’s investors?
ENKORE International Enterprises, European Commission, Genextra, and Pagani Ventures have invested in TargImmune Therapeutics.
-
Who are TargImmune Therapeutics’s competitors?
Anaveon, Genetix Biotherapeutics, Alaunos Therapeutics, Inovio Pharmaceuticals, and Virometix are some of the 15 competitors of TargImmune Therapeutics.
-
When was TargImmune Therapeutics acquired?
TargImmune Therapeutics was acquired on 14-Mar-2025.
-
Who acquired TargImmune Therapeutics?
TargImmune Therapeutics was acquired by iOncologi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process